Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase I study evaluating rovalpituzumab tesirine (ROVA-T) in the frontline treatment of patients with extensive-stage small-cell lung cancer (NCT02819999). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.